Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Incyte Corporation    INCY

INCYTE CORPORATION

(INCY)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Incyte Corporation : annual earnings release

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/11/2019 | 09:15am EDT

The company will report its earnings for FY 2018 on 02/14/2019. Generally, the company reports earnings in line with the consensus. In recent months, the 15 analysts from Thomson Reuters consensus have revised their EPS estimates downward.

Annual earnings per share is expected at 0.41 USD for 2018 (- 126.8% from 2017). A summary of annual publications and estimates is available below.

Annual results2015201620172018 (e)2019 (e)
Sales
Million $
Released
Forecast
Spread

736
1 106
1 106
0,01%
1 536
1 518
1,2%



2 018
Operating income (EBITDA)
Million $
Released
Forecast
Spread
95,5
48,6
97%
203
199
2,1%
-192
-171
-12%

294

484
Operating profit (EBIT)
Million $
Released
Forecast
Spread
50,7
14,4
251%
145
118
23%
-244
-218
-12%

211

437
Pre-Tax Profit (EBT)
 
Released
Forecast
Spread










Net income
Million $
Released
Forecast
Spread

-34,7
101
120
-16%
-313
-236
-33%

100

292
EPS
 $
Released
Forecast
Spread
0,03
-0,19
116%
0,54
0,62
-13%
-1,53
-1,17
-31%

0,41

1,36
Announcement Date11/30/-000102/14/201702/15/2018
Stocks mentioned in the article
ChangeLast1st jan.
INCYTE CORPORATION -3.92% 78.51 Delayed Quote.28.50%
THOMSON REUTERS CORP 0.59% 89.83 Delayed Quote.34.04%

© MarketScreener.com 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on INCYTE CORPORATION
07/11INCYTE : Summary ToggleIncyte to Report Second Quarter Financial Results
PU
07/11INCYTE : to Report Second Quarter Financial Results
BU
07/02INCYTE : Summary ToggleIncyte and Zai Lab Announce Collaboration and License Agr..
PU
06/28INCYTE : New Global Cholangiocarcinoma Alliance announces founding supporters
AQ
06/17INCYTE : Announces Positive Results from a Phase 2 Study of Ruxolitinib Cream in..
AQ
06/15INCYTE : Summary ToggleIncyte Announces Positive Results from a Phase 2 Study of..
PU
06/15INCYTE : Announces Positive Results from a Phase 2 Study of Ruxolitinib Cream in..
BU
06/04INCYTE : Summary ToggleIncyte Announces First Patient Treated in Phase 3 Clinica..
PU
06/04INCYTE : Announces First Patient Treated in Phase 3 Clinical Trial of Pemigatini..
BU
06/04INCYTE : New Data from GEOMETRY mono-1 Study Show Clinically Meaningful Results ..
AQ
More news
Financials (USD)
Sales 2019 2 075 M
EBIT 2019 297 M
Net income 2019 323 M
Finance 2019 1 760 M
Yield 2019 -
P/E ratio 2019 54,2x
P/E ratio 2020 38,3x
EV / Sales2019 7,26x
EV / Sales2020 6,08x
Capitalization 16 836 M
Chart INCYTE CORPORATION
Duration : Period :
Incyte Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INCYTE CORPORATION
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 89,29  $
Last Close Price 78,51  $
Spread / Highest target 43,9%
Spread / Average Target 13,7%
Spread / Lowest Target -4,47%
EPS Revisions
Managers
NameTitle
Hervé Hoppenot Chairman, President & Chief Executive Officer
Steven H. Stein Chief Medical Officer & Executive Vice President
Michael Morrissey Senior VP & Head-Global Technical Operations
Lothar H. Finke Head-Clinical Development & General Manager-Japan
Dashyant Dhanak Chief Scientific Officer & Executive VP
Sector and Competitors
1st jan.Capitalization (M$)
INCYTE CORPORATION28.50%17 522
IQVIA HOLDINGS INC34.52%30 823
LONZA GROUP33.10%25 850
CELLTRION, INC.--.--%20 040
EXACT SCIENCES CORPORATION82.06%14 987
SEATTLE GENETICS, INC.34.26%12 302